TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26282726
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg (D150)
Study: 16085437
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 2g
Study: 16085437
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 1g
Study: 12823597
Drug: All peginterferon
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All peginterferon alpha‐2a (40 kDa) doses combined
Study: 6797778
Drug: Non-selective beta-blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blockade (pindolol, 15 mg daily)
Study: 6797778
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 weeks treatment)
Study: 23715889
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid filler (Glytone 1, HA concentration: 14 mg/g)
Study: 23715889
Drug: Saline physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline physiological solution (control)
Study: 21482607
Drug: Weekly healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly healthy lifestyle group (intervention)
Study: 21482607
Drug: Monthly school-readiness
Normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly school-readiness group (control)
Study: 17292880
Drug: Perhexiline pre-treatment
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline pre-treatment with Nitroglycerin
Study: 9621474
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion and artificial rupture of membrane (ARM)
Study: 2646895
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg once daily
Study: 2073672
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg b.i.d.
Study: 19033829
Drug: Web-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based family treatment program
Study: 8825538
Drug: Doxacurium 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxacurium 0.075 mg.kg‐1 (Group 2)
Study: 1909485
Drug: Lisuride alone
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride alone (1.43 +/- 0.10 mg)
Study: 6195911
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg every 8 hours
Study: 6195911
Drug: Acebutolol, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol, 300 mg every 8 hours
Study: 28952704
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 5-reductase inhibitors and blockers
Study: 17496655
Drug: Bilateral cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral cochlear implants
Study: 18580613
Drug: Immediate antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiretroviral therapy (ART)
Study: 25765099
Drug: rhGH +
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH + 150 rhIGF-1 (45/150 µg/kg)
Study: 12782545
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day oral androstenedione
Study: 3792426
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg every 6 h)
Study: 3792426
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg every 12 h)
Study: 31567714
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL isotonic saline (control group)
Study: 20433527
Drug: Lactotripeptides dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides dosed twice daily
Study: 20433527
Drug: Lactotripeptides in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides in treatment-naive patients
Study: 20433527
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in treatment-naive patients
Study: 12390641
Drug: Children's ibuprofen
Normalized name: Children's Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children's ibuprofen suspension (7.5 mg/kg, p.o.)
Study: 797088
Drug: Vistarin injections
Normalized name: Vistaril Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistarin injections
Study: 797088
Drug: Varicocide injections
Normalized name: AESCULUS CHINENSIS WHOLE 4 g in 100 g / ARNICA CORDIFOLIA WHOLE 3 g in 100 g TOPICAL PATCH [Rotosxika Varicoce Veins Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicocide injections
Study: 16533414
Drug: Pulsed-dose oxygen-conserving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dose oxygen-conserving device (PDOCD)
Study: 16533414
Drug: Pulsed-dose oxygen-conserving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dose oxygen-conserving device (PDOCD) with sensitive triggering sensitivity
Study: 12648029
Drug: Ritalin LA
Normalized name: Ritalin LA
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritalin LA 20 mg capsule
Study: 12648029
Drug: Concerta 18
Normalized name: Concerta 18mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerta 18 mg tablet
Study: 11197318
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch (21 mg for 6 weeks, then 14 mg for weeks 7-8, and 7 mg for weeks 9-10)
Study: 17641254
Drug: Topiramate 400
Normalized name: topiramate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 400 mg/day
Study: 25394040
Drug: CVC 100
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC 100 mg
Study: 25394040
Drug: CVC 200
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC 200 mg
Study: 9305418
Drug: Nicotine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.8 mg)
Study: 6376480
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg)
Study: 9305418
Drug: Nicotine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.8 mg) + Haloperidol (5 mg)
Study: 9305418
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Haloperidol (5 mg)
Study: 7818614
Drug: Dosing rules
Normalized name: Rubes nigrum seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing rules for phenytoin (PHT)
Study: 16413249
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rabeprazole
Study: 10714565
Drug: Mutant combination
Normalized name: Streptococcus mutans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutant combination 601 + 215Y/F
Study: 9370846
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg.kg-1
Study: 3514473
Drug: Ofloxacin (OFX)
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin (OFX) 2 X 200 mg/day (n = 21)
Study: 3514473
Drug: Doxycycline (D)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (D) 2 X 100 mg/day (n = 20)
Study: 12860868
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lexipafant (10 mg)
Study: 12860868
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lexipafant (100 mg)
Study: 10100181
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days + chlormadinone acetate for 5 days
Study: 10100181
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 1.25 mg/day for 21 days + chlormadinone acetate for 5 days
Study: 17895912
Drug: Moderate vitamins
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate vitamins (vitamin C (300 mg) and E (75 IU) and folic acid (1 mg))
Study: 17895912
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamins (vitamin C (2 g) and E (800 IU), and folic acid (5 mg))
Study: 11136518
Drug: Subsequent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent use of larger doses of antimony
Study: 2936772
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 gm/day for 4 weeks, then 333 mg/day for 8 weeks)
Study: 2936772
Drug: Tetracycline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (1 gm/day for 4 weeks, then 500 mg/day for 8 weeks)
Study: 22854666
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg hepatitis B vaccine
Study: 18587236
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg i.v. 5‐MTHF
Study: 8027279
Drug: Follicle Stimulating
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follicle Stimulating Hormone (FSH) 225 IU/day for 5 days
Study: 8027279
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml/day for 5 days
Study: 2524571
Drug: Chlorhexidine dihydrochloride
Normalized name: CHLORHEXIDINE DIHYDROCHLORIDE
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine dihydrochloride lozenges (5 mg, sucked three times daily after meals for 2 weeks)
Study: 2524571
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (all ingredients except chlorhex HCl)
Study: 29044395
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering (mean reduction of about 1.0 mmol/L) in men with average cholesterol and no CHD
Study: 29044395
Drug: Lowest cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest cholesterol group (mean 4.0 mmol/L)
Study: 29044395
Drug: Highest cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest cholesterol group (mean 8.8 mmol/L)
Study: 25816315
Drug: Inhaled UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled UMEC/VI 62.5/25 μg (delivering 55/22 μg)
Study: 25816315
Drug: UMEC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 62.5 μg (monotherapy)
Study: 25816315
Drug: UMEC 125
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 125 μg (monotherapy)
Study: 25816315
Drug: VI 25
Normalized name: VITRAKVI 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VI 25 μg (monotherapy)
Study: 23609838
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri NCIMB 30242
Study: 21840164
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) + Venlafaxine XR
Study: 7921222
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) (5-20 micrograms every 120 min)
Study: 31970675
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy alone (Control group)
Study: 20488885
Drug: Rituximab 2
Normalized name: hyaluronidase-rituximab 23,400 units-1400 mg/11.7 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 2 x 1000 mg + MTX
Study: 16166411
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment for late-life depression with Cluster C PDs
Study: 16166411
Drug: Continuation or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation or maintenance treatment for late-life depression with Cluster C PDs
Study: 16166411
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment for late-life depression with Cluster C PDs and residual depressive symptoms
Study: 10548673
Drug: Forced use
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced use therapy (immobilization of the unaffected arm combined with intensive training)
Study: 10548673
Drug: Bimanual training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual training (reference therapy based on Neuro‐Developmental Treatment)
Study: 10548673
Drug: Forced use
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced use therapy
Study: 7572902
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg daily)
Study: 24292519
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ATG
Study: 21890719
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed antiretroviral therapy
Study: 7745506
Drug: Synthetic surfactant
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic surfactant (5 ml/kg dose)
Study: 14578781
Drug: Low-molecular-weight dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight dextran 20 cc/hour for 120 hours (n=32)
Study: 14578781
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/day for 120 hours (n=27)
Study: 22136516
Drug: DHEA-S (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA-S (100 mg daily for 3 months)
Study: 20701787
Drug: Intensive Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Insulin Treatment (IIT)
Study: 378804
Drug: 193 mg
Normalized name: kaolin 193 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 193 mg Fe++ daily for 4 weeks
Study: 30907187
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 2 or 4 IU daily subcutaneous injection
Study: 30907187
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 4 IU - 6 weeks pretreatment
Study: 30907187
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) high-quality embryo rate
Study: 24722160
Drug: Vandetanib plus
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib plus gemcitabine (V/G)
Study: 9808597
Drug: ST-segment depression,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST-segment depression, inverted T waves in >/=5 leads, TnT >/=0.1 microg/L, TnI >/=0.5 microg/L, myoglobin >/=40 microg/L, female sex, age >/=65 years
Study: 7710149
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg sumatriptan SC
Study: 2560514
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC (10 mg t.i.d. for 3 days and on the morning of the fourth day)
Study: 2560514
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of THC by inhalation (18 mg/marijuana cigarette)
Study: 6166128
Drug: Antibiotics combined
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics combined with pepsin-treated human gamma globulin (Gamma-Venin)
Study: 11678828
Drug: Pegvisomant (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (80 mg as a single subcutaneous injection)
Study: 3646618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine hospital feeding of up to 30 ml of sterile water at 4 HOL and up to 30 ml of formula at 8 HOL)
Study: 20645395
Drug: Pharmacological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological interventions (including antioxidants, anti-inflammatory drugs, vasodilators, pharmacological preconditioning, glucose infusion)
Study: 15701468
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy (loop diuretics, ACE inhibitors/ARBs, beta-blockers, spironolactone)
Study: 12083314
Drug: Phytostanol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytostanol treatment (3 g/d in 3 servings)
Study: 12083314
Drug: Phytostanol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytostanol treatment
Study: 10087722
Drug: Dexfenfluramine 30
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 30 mg/day
Study: 1971586
Drug: Xamoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (0.2 mg kg‐1 by infusion over 5 min)
Study: 31969363
Drug: Self-reported computerised
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported computerised history taking (CHT) using a tablet.
Study: 26500169
Drug: SMART-CPT (hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART-CPT (hybrid treatment integrating CogSMART into cognitive processing therapy)
Study: 26500169
Drug: Standard CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CPT (Cognitive Processing Therapy)
Study: 25059982
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg/day)
Study: 24186866
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metformin and Sitagliptin
Study: 19205719
Drug: Topical levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical levofloxacin four times per day in both eyes for at least 3 days
Study: 2967310
Drug: Acitretin 75
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 75 mg daily
Study: 2967310
Drug: Acitretin 10
Normalized name: acitretin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 10 mg daily
Study: 31743233
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg/day)
Study: 22056247
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily, with possible increases to 7 mg and 10 mg)
Study: 6373961
Drug: B subunit
Normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit (low dose, 1.0 mg)
Study: 28742932
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy/cognitive-behavioral therapy (MET/CBT)
Study: 21479749
Drug: Commercial immediate-release
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial immediate-release Napilac® capsules
Study: 23770005
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg golimumab
Study: 17710801
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of compound Danshen injection and oral aspirin
Study: 15100686
Drug: Aspirin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (dose not specified)
Study: 10432262
Drug: 6-month exercise
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month exercise protocol (daily performance of five shoulder exercises: two for stretching anterior shoulder musculature and three for strengthening posterior shoulder musculature)
Study: 7580546
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with supportive care
Study: 7580546
Drug: Radical radiotherapy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiotherapy plus chemotherapy
Study: 2024984
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin 0.01%
Study: 2024984
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin 0.001%
Study: 2024984
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin 0.05%, 0.01%, 0.001%
Study: 6941670
Drug: Letter identification
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letter identification task (L) in HT group
Study: 6941670
Drug: Letter identification
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letter identification task (L) in NT group
Study: 6322961
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus razoxane (daily schedule: 250 mg per day)
Study: 28771784
Drug: Standard or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard or experimental treatment
Study: 24062200
Drug: Control patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patch with low-dose capsaicin 0.075% cream
Study: 20416218
Drug: Compound glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound glycyrrhizin treatment
Study: 10655967
Drug: Broccoli meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli meal (300 g/d)
Study: 10655967
Drug: Green peas
Normalized name: green english pea allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green peas meal (300 g/d)